DK1021410T3 - Prostaglandinagonister og deres anvendelse til behandling af knogletilstande - Google Patents

Prostaglandinagonister og deres anvendelse til behandling af knogletilstande

Info

Publication number: DK1021410T3
Authority: DK; Denmark
Prior art keywords: treatment; bone conditions; prostaglandin agonists; prostaglandin; agonists
Prior art date: 1997-10-10

Application number

DK98944169T

Other languages

English (en)

Inventor

Robert Louis Rosati

Kimberly O'keefe Cameron

Bruce Allen Lefker

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-10

Filing date

1998-10-05

Publication date

2007-04-02

1998-10-05 Application filed by Pfizer filed Critical Pfizer

2007-04-02 Application granted granted Critical

2007-04-02 Publication of DK1021410T3 publication Critical patent/DK1021410T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyridine Compounds (AREA)
Furan Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Thiazole And Isothizaole Compounds (AREA)
Pyrrole Compounds (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

DK98944169T 1997-10-10 1998-10-05 Prostaglandinagonister og deres anvendelse til behandling af knogletilstande DK1021410T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US6172797P	1997-10-10	1997-10-10
PCT/IB1998/001540 WO1999019300A1 (en)	1997-10-10	1998-10-05	Prostaglandin agonists and their use to treat bone disorders

Publications (1)

Publication Number	Publication Date
DK1021410T3 true DK1021410T3 (da)	2007-04-02

Family

ID=22037728

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK98944169T DK1021410T3 (da)	1997-10-10	1998-10-05	Prostaglandinagonister og deres anvendelse til behandling af knogletilstande

Country Status (45)

Country	Link
US (2)	US6498172B1 (da)
EP (1)	EP1021410B1 (da)
JP (3)	JP3664651B2 (da)
KR (1)	KR100369697B1 (da)
CN (2)	CN1211367C (da)
AP (1)	AP1156A (da)
AR (1)	AR015954A1 (da)
AT (1)	ATE349428T1 (da)
AU (1)	AU731509B2 (da)
BG (1)	BG65238B1 (da)
BR (1)	BR9813028A (da)
CA (1)	CA2305548C (da)
DE (1)	DE69836752T2 (da)
DK (1)	DK1021410T3 (da)
DZ (1)	DZ2621A1 (da)
EA (1)	EA003396B1 (da)
ES (1)	ES2277390T3 (da)
GT (2)	GT199800158AA (da)
HK (1)	HK1031884A1 (da)
HN (1)	HN1998000157A (da)
HR (1)	HRP20000201B1 (da)
HU (1)	HUP0100101A3 (da)
ID (1)	ID24836A (da)
IL (2)	IL134851A0 (da)
IS (1)	IS5405A (da)
MA (1)	MA26551A1 (da)
MY (1)	MY129189A (da)
NO (1)	NO316733B1 (da)
NZ (1)	NZ503165A (da)
OA (1)	OA11346A (da)
PA (1)	PA8461301A1 (da)
PE (1)	PE121199A1 (da)
PL (1)	PL340014A1 (da)
PT (1)	PT1021410E (da)
RS (1)	RS50012B (da)
SA (2)	SA06260449B1 (da)
SI (1)	SI1021410T1 (da)
SK (1)	SK286136B6 (da)
TN (1)	TNSN98182A1 (da)
TR (1)	TR200000927T2 (da)
TW (1)	TW570913B (da)
UA (1)	UA67754C2 (da)
UY (1)	UY25204A1 (da)
WO (1)	WO1999019300A1 (da)
ZA (1)	ZA989230B (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA67754C2 (uk)	1997-10-10	2004-07-15	Пфайзер, Інк.	Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
EP1000619A3 (en) *	1998-06-23	2002-07-24	Pfizer Products Inc.	Method for treating glaucoma
IL145122A0 (en)	1999-03-05	2002-06-30	Procter & Gamble	C16 unsaturated fp-selective prostaglandin analogs
TWI262185B (en) *	1999-10-01	2006-09-21	Eisai Co Ltd	Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
ATE327751T1 (de)	2000-01-31	2006-06-15	Pfizer Prod Inc	Verwendung von aktivatoren des prostaglandinrezeptores 4 zur behandlung von akuter oder chronischer niereninsuffizienz
US20010056060A1 (en) *	2000-02-07	2001-12-27	Cameron Kimberly O.	Treatment of osteoporsis with EP2/EP4 receptor selective agonists
US20020013294A1 (en)	2000-03-31	2002-01-31	Delong Mitchell Anthony	Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en)	2000-03-31	2002-11-21	Delong Michell Anthony	Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
WO2003043576A2 (en) *	2001-11-20	2003-05-30	Depuy Products, Inc.	Flowable osteogenic and chondrogenic compositions
WO2003045351A1 (en)	2001-11-30	2003-06-05	Pfizer Inc.	Controlled release polymeric compositions of bone growth promoting compounds
WO2003045371A1 (en) *	2001-11-30	2003-06-05	Pfizer Products Inc.	Pharmaceutical compositions and methods for administering ep2 receptor selective agonists
WO2003064391A1 (en) *	2002-01-31	2003-08-07	Pfizer Products Inc.	Metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid
JP2005532291A (ja) *	2002-04-12	2005-10-27	ファイザー株式会社	抗炎症薬および鎮痛薬としてのピラゾール化合物
JP2005527624A (ja)	2002-05-24	2005-09-15	ファーマシアコーポレイション	スルホン肝ｘ受容体調節因子
MXPA04011691A (es)	2002-05-24	2005-09-12	Pharmacia Corp	Moduladores del receptor x anilino hepaticos.
JP2006021998A (ja) *	2002-07-18	2006-01-26	Ono Pharmaceut Co Ltd	Ｅｐ２アゴニストを有効成分とする月経困難症治療剤
DK2465537T3 (da)	2002-10-10	2016-09-19	Ono Pharmaceutical Co	Mikrosfærer, der omfatter ono-1301
GB0302094D0 (en)	2003-01-29	2003-02-26	Pharmagene Lab Ltd	EP4 receptor antagonists
CA2518193A1 (en) *	2003-03-04	2004-09-16	Pfizer Products Inc.	Use of ep2 selective receptor agonists in medical treatment
EP2422814A1 (en)	2003-07-25	2012-02-29	Ono Pharmaceutical Co., Ltd.	Remedy for cartilage-related diseases
WO2005027931A1 (en) *	2003-09-19	2005-03-31	Pfizer Products Inc.	Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
GB0324269D0 (en)	2003-10-16	2003-11-19	Pharmagene Lab Ltd	EP4 receptor antagonists
US20050203086A1 (en) *	2004-03-04	2005-09-15	Pfizer Inc.	Methods of treatment using an EP2 selective receptor agonist
CA2571482A1 (en) *	2004-06-21	2005-12-29	Pharmacia & Upjohn Company Llc	Pyk2 inhibitors for stimulation of osteoblast function
US7858650B2 (en)	2004-10-22	2010-12-28	Ono Pharmaceutical Co., Ltd.	Medicinal composition for inhalation
US8604055B2 (en)	2004-12-31	2013-12-10	Dr. Reddy's Laboratories Ltd.	Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
KR101238525B1 (ko)	2004-12-31	2013-02-28	레디 유에스 테라퓨틱스 인코포레이티드	Ｃｅｔｐ 저해제로서의 신규 벤질아민 유도체
CN101237885B (zh)	2005-06-03	2011-01-19	小野药品工业株式会社	神经再生和/或保护剂
US7915316B2 (en)	2005-08-22	2011-03-29	Allergan, Inc	Sulfonamides
US7696235B2 (en)	2005-08-29	2010-04-13	Allergan, Inc.	EP2 receptor agonists for treating glaucoma
KR101088942B1 (ko) *	2006-07-28	2011-12-01	화이자 프로덕츠 인코포레이티드	Ｅｐ2 작용제
CN101495452B (zh) *	2006-07-28	2012-04-25	辉瑞产品公司	Ep2激动剂
CA2669763C (en)	2006-11-16	2015-02-17	Bayer Schering Pharma Aktiengesellschaft	Ep2 and ep4 agonists as agents for the treatment of influenza a viral infection
US9394520B2 (en) *	2006-12-08	2016-07-19	University Of Rochester	Expansion of hematopoietic stem cells
ES2545121T3 (es) *	2007-08-21	2015-09-08	Senomyx, Inc.	Compuestos que inhiben (bloquean) el sabor amargo en composiciones, y uso de los mismos
CN101842356A (zh) *	2007-08-29	2010-09-22	辉瑞产品公司	(3-(((4-叔丁基苄基)-(吡啶-3-磺酰基)-氨基)-甲基)-苯氧基)-乙酸钠盐或其水合物的多晶型体及其制备方法
WO2009027803A2 (en) *	2007-08-29	2009-03-05	Pfizer Products Inc.	Polymorphs of (3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)- phenoxy)-acetic acid, free acid
US20110046385A1 (en) *	2007-08-29	2011-02-24	Pfizer Products Inc.	Polymorphs Of Prostaglandin Agonists And Methods For Making The Same
AU2009224329B2 (en) *	2008-03-12	2013-11-07	Ube Corporation	Pyridylaminoacetic acid compound
EP2149551A1 (de)	2008-07-30	2010-02-03	Bayer Schering Pharma AG	N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de)	2008-07-30	2010-02-03	Bayer Schering Pharma Aktiengesellschaft	Indolylamide als Modulatoren des EP2-Rezeptors
EP2149552A1 (de)	2008-07-30	2010-02-03	Bayer Schering Pharma AG	5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
KR101681347B1 (ko)	2009-03-30	2016-11-30	우베 고산 가부시키가이샤	녹내장의 치료 또는 예방을 위한 의약 조성물
WO2010116270A1 (en)	2009-04-10	2010-10-14	Pfizer Inc.	Ep2/4 agonists
AU2010336248A1 (en)	2009-12-25	2012-08-02	Ube Industries, Ltd.	Aminopyridine compound
WO2012036512A2 (ko)	2010-09-16	2012-03-22	연세대학교 산학협력단	중간엽 줄기세포의 연골 세포로의 분화 유도를 위한 화합물의 용도
JP5964965B2 (ja)	2011-08-18	2016-08-03	ドクターレディズラボラトリーズリミテッド	コレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての置換複素環式アミン化合物
JP6140168B2 (ja)	2011-09-27	2017-05-31	ドクターレディズラボラトリーズリミテッド	アテローム性動脈硬化症の処置のために有用なコレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての５−ベンジルアミノメチル−６−アミノピラゾロ［３，４−ｂ］ピリジン誘導体
US8772541B2 (en) *	2011-12-15	2014-07-08	University of Pittsburgh—of the Commonwealth System of Higher Education	Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases
US20150272874A1 (en)	2012-10-29	2015-10-01	Cardio Incorporated	Pulmonary disease-specific therapeutic agent
CA2902624C (en)	2013-02-28	2021-05-18	Takeda Pharmaceutical Company Limited	Method for producing sulfonyl chloride compound
TW201527282A (zh)	2013-03-28	2015-07-16	Ube Industries	取代聯芳基化合物
US9968716B2 (en)	2013-10-15	2018-05-15	Ono Pharmaceutical Co., Ltd.	Drug-eluting stent graft
JP2017206444A (ja) *	2014-09-26	2017-11-24	宇部興産株式会社	置換フェニル化合物
CN114591227A (zh) *	2021-12-28	2022-06-07	上海冬洋生物科技有限公司	一种ep2受体选择性的前列腺素e2激动剂的制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR897566A (fr)	1942-08-28	1945-03-26	Bopp & Reuther Gmbh	Machine à rotors
US3442890A (en)	1965-06-15	1969-05-06	Mead Johnson & Co	Substituted 3-benzazocin-16-ones
US3528961A (en)	1966-08-16	1970-09-15	Allied Chem	Monoazo dyes from e-caprolactam
US3780095A (en)	1970-04-08	1973-12-18	Byk Gulden Lomberg Chem Fab	Acylated anilino-carboxylic acids and their salts
US3987091A (en)	1973-04-12	1976-10-19	Merck & Co., Inc.	11,12-secoprostaglandins
US4033996A (en)	1973-04-25	1977-07-05	Merck & Co., Inc.	8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins
JPS5019756A (da)	1973-06-25	1975-03-01
SE7414770L (da)	1973-12-13	1975-06-16	Merck & Co Inc
DK366475A (da)	1974-08-30	1976-03-01	Merck & Co Inc	Fremgangsmade til fremstilling af aryloxy- eller arylthioholdige secoprostaglandiner
US4055596A (en) *	1974-09-13	1977-10-25	Merck & Co., Inc.	11,12-Seco-prostaglandins
US3991106A (en)	1974-09-13	1976-11-09	Merck & Co., Inc.	16-Ethers of 8-aza-9-dioxothia-11,12-seco-prostaglandins
US4175203A (en)	1976-12-17	1979-11-20	Merck & Co., Inc.	Interphenylene 11,12-secoprostaglandins
US4112236A (en)	1977-04-04	1978-09-05	Merck & Co., Inc.	Interphenylene 8-aza-9-dioxothia-11,12-secoprostaglandins
US4097601A (en) *	1977-08-26	1978-06-27	Pfizer Inc.	Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins
US4243678A (en)	1977-12-30	1981-01-06	Byk Gulden Lomberg Chemische Fabrik Gmbh	Acylhydrocarbylaminoalkanoic acids, compositions and uses
DE3000377A1 (de)	1980-01-07	1981-07-09	Boehringer Mannheim Gmbh, 6800 Mannheim	Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
DE3042482A1 (de)	1980-11-11	1982-06-24	A. Nattermann & Cie GmbH, 5000 Köln	N-benzoyl- (omega) -anilinoalkancarbonsaeuren, -salze und -ester, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
EP0068968B1 (fr)	1981-06-16	1985-09-18	Choay S.A.	Nouveaux médicaments contenant à titre de substance active des composés du type arylbenzènesulfonamide et leurs procédés de préparation
FI832935A (fi)	1982-08-20	1984-02-21	Midit	Derivat av w-aminosyror, deras framstaellning samt dessa derivat innehaollande blandningar
DE3719046A1 (de)	1987-06-06	1988-12-15	Basf Ag	Verwendung von salzen von sulfonamidcarbonsaeuren als korrosionsinhibitoren in waessrigen systemen
US5084466A (en) *	1989-01-31	1992-01-28	Hoffmann-La Roche Inc.	Novel carboxamide pyridine compounds which have useful pharmaceutical utility
US5081152A (en)	1989-07-05	1992-01-14	Kotobuki Seiyaku Co., Ltd.	Azulene derivatives as thromboxane a2 and prostaglandin endoperoxide receptor antagonist
JPH0467105A (ja) *	1990-07-09	1992-03-03	Nippon Telegr & Teleph Corp <Ntt>	偏波保持光ファイバ
GB9110722D0 (en) *	1991-05-17	1991-07-10	Fujisawa Pharmaceutical Co	Amine derivatives
GB9116732D0 (en) *	1991-08-02	1991-09-18	Fujisawa Pharmaceutical Co	Indole derivatives
CA2113787A1 (en) *	1993-01-29	1994-07-30	Nobuyuki Hamanaka	Carbocyclic sulfonamides
HN1996000101A (es) *	1996-02-28	1997-06-26	Inc Pfizer	Terapia combinada para la osteoporosis
DE19648793A1 (de) *	1996-11-26	1998-05-28	Basf Ag	Neue Benzamide und deren Anwendung
UA59384C2 (uk) *	1996-12-20	2003-09-15	Пфайзер, Інк.	Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
AUPO440696A0 (en) *	1996-12-30	1997-01-23	Fujisawa Pharmaceutical Co., Ltd.	New use
UA67754C2 (uk)	1997-10-10	2004-07-15	Пфайзер, Інк.	Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
WO2003045371A1 (en) *	2001-11-30	2003-06-05	Pfizer Products Inc.	Pharmaceutical compositions and methods for administering ep2 receptor selective agonists
WO2003064391A1 (en) *	2002-01-31	2003-08-07	Pfizer Products Inc.	Metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid

1998
- 1998-05-10 UA UA2000042002A patent/UA67754C2/uk unknown
- 1998-10-05 EA EA200000298A patent/EA003396B1/ru not_active IP Right Cessation
- 1998-10-05 ES ES98944169T patent/ES2277390T3/es not_active Expired - Lifetime
- 1998-10-05 AT AT98944169T patent/ATE349428T1/de not_active IP Right Cessation
- 1998-10-05 SK SK475-2000A patent/SK286136B6/sk not_active IP Right Cessation
- 1998-10-05 PL PL98340014A patent/PL340014A1/xx unknown
- 1998-10-05 US US09/367,970 patent/US6498172B1/en not_active Expired - Fee Related
- 1998-10-05 IL IL13485198A patent/IL134851A0/xx active IP Right Grant
- 1998-10-05 NZ NZ503165A patent/NZ503165A/en unknown
- 1998-10-05 EP EP98944169A patent/EP1021410B1/en not_active Expired - Lifetime
- 1998-10-05 TR TR2000/00927T patent/TR200000927T2/xx unknown
- 1998-10-05 WO PCT/IB1998/001540 patent/WO1999019300A1/en active IP Right Grant
- 1998-10-05 BR BR9813028-5A patent/BR9813028A/pt not_active Application Discontinuation
- 1998-10-05 CN CNB988100266A patent/CN1211367C/zh not_active Expired - Fee Related
- 1998-10-05 KR KR10-2000-7003851A patent/KR100369697B1/ko not_active IP Right Cessation
- 1998-10-05 DK DK98944169T patent/DK1021410T3/da active
- 1998-10-05 PT PT98944169T patent/PT1021410E/pt unknown
- 1998-10-05 JP JP2000515873A patent/JP3664651B2/ja not_active Expired - Fee Related
- 1998-10-05 CA CA002305548A patent/CA2305548C/en not_active Expired - Fee Related
- 1998-10-05 ID IDW20000647A patent/ID24836A/id unknown
- 1998-10-05 CN CNA2004100385354A patent/CN1566096A/zh active Pending
- 1998-10-05 DE DE69836752T patent/DE69836752T2/de not_active Expired - Lifetime
- 1998-10-05 HU HU0100101A patent/HUP0100101A3/hu unknown
- 1998-10-05 AU AU91815/98A patent/AU731509B2/en not_active Ceased
- 1998-10-05 SI SI9830873T patent/SI1021410T1/sl unknown
- 1998-10-05 RS YUP-184/00A patent/RS50012B/sr unknown
- 1998-10-06 HN HN1998000157A patent/HN1998000157A/es unknown
- 1998-10-06 PA PA19988461301A patent/PA8461301A1/es unknown
- 1998-10-07 MY MYPI98004598A patent/MY129189A/en unknown
- 1998-10-07 TW TW087116614A patent/TW570913B/zh not_active IP Right Cessation
- 1998-10-08 UY UY25204A patent/UY25204A1/es not_active IP Right Cessation
- 1998-10-08 AP APAP/P/1998/001356A patent/AP1156A/en active
- 1998-10-09 PE PE1998000956A patent/PE121199A1/es not_active Application Discontinuation
- 1998-10-09 AR ARP980105053A patent/AR015954A1/es active IP Right Grant
- 1998-10-09 ZA ZA9809230A patent/ZA989230B/xx unknown
- 1998-10-09 GT GT199800158AK patent/GT199800158AA/es unknown
- 1998-10-09 GT GT199800158A patent/GT199800158A/es unknown
- 1998-10-09 TN TNTNSN98182A patent/TNSN98182A1/fr unknown
- 1998-10-09 MA MA25288A patent/MA26551A1/fr unknown
- 1998-10-10 DZ DZ980231A patent/DZ2621A1/xx active
- 1998-11-23 SA SA6260449A patent/SA06260449B1/ar unknown
- 1998-11-23 SA SA98190804A patent/SA98190804B1/ar unknown
2000
- 2000-03-02 IL IL134851A patent/IL134851A/en not_active IP Right Cessation
- 2000-03-14 IS IS5405A patent/IS5405A/is unknown
- 2000-03-31 OA OA1200000097A patent/OA11346A/en unknown
- 2000-04-05 NO NO20001754A patent/NO316733B1/no not_active IP Right Cessation
- 2000-04-07 BG BG104315A patent/BG65238B1/bg unknown
- 2000-04-10 HR HR980440A patent/HRP20000201B1/xx not_active IP Right Cessation
2001
- 2001-04-12 HK HK01102626A patent/HK1031884A1/xx not_active IP Right Cessation
2002
- 2002-09-25 US US10/256,198 patent/US7442702B2/en not_active Expired - Fee Related
2003
- 2003-06-12 JP JP2003167713A patent/JP4031736B2/ja not_active Expired - Fee Related
2007
- 2007-04-25 JP JP2007115825A patent/JP4796006B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
NZ503165A (en)	2001-07-27
AR015954A1 (es)	2001-05-30
BG65238B1 (bg)	2007-09-28
CN1275123A (zh)	2000-11-29
AU731509B2 (en)	2001-03-29
HUP0100101A2 (hu)	2001-06-28
SK286136B6 (sk)	2008-04-07
TNSN98182A1 (fr)	2005-03-15
KR20010031035A (ko)	2001-04-16
ZA989230B (en)	2000-04-10
EP1021410B1 (en)	2006-12-27
JP4031736B2 (ja)	2008-01-09
BR9813028A (pt)	2000-08-15
US7442702B2 (en)	2008-10-28
GT199800158AA (es)	2000-04-01
SI1021410T1 (sl)	2007-06-30
IS5405A (is)	2000-03-14
HUP0100101A3 (en)	2001-12-28
CN1211367C (zh)	2005-07-20
HRP20000201A2 (en)	2000-06-30
CN1566096A (zh)	2005-01-19
ES2277390T3 (es)	2007-07-01
JP3664651B2 (ja)	2005-06-29
AP1156A (en)	2003-06-30
CA2305548A1 (en)	1999-04-22
WO1999019300A1 (en)	1999-04-22
JP2001519414A (ja)	2001-10-23
ID24836A (id)	2000-08-24
AU9181598A (en)	1999-05-03
UA67754C2 (uk)	2004-07-15
PT1021410E (pt)	2007-02-28
JP2007246532A (ja)	2007-09-27
CA2305548C (en)	2008-12-02
JP4796006B2 (ja)	2011-10-19
OA11346A (en)	2003-12-11
EP1021410A1 (en)	2000-07-26
SA98190804B1 (ar)	2006-07-30
SA98190804A (ar)	2005-12-03
HRP20000201B1 (en)	2003-06-30
TW570913B (en)	2004-01-11
US20030078261A1 (en)	2003-04-24
DE69836752T2 (de)	2007-10-11
IL134851A0 (en)	2001-05-20
JP2004155759A (ja)	2004-06-03
RS50012B (sr)	2008-09-29
US6498172B1 (en)	2002-12-24
GT199800158A (es)	2000-04-01
PE121199A1 (es)	1999-12-02
YU18400A (sh)	2003-08-29
EA200000298A1 (ru)	2000-10-30
MA26551A1 (fr)	2004-12-20
UY25204A1 (es)	2000-12-29
NO20001754L (no)	2000-06-07
PA8461301A1 (es)	2000-05-24
AP9801356A0 (en)	1998-12-31
SA06260449B1 (ar)	2007-08-07
HK1031884A1 (en)	2001-06-29
NO20001754D0 (no)	2000-04-05
DZ2621A1 (fr)	2003-03-08
ATE349428T1 (de)	2007-01-15
TR200000927T2 (tr)	2000-11-21
NO316733B1 (no)	2004-04-14
BG104315A (en)	2000-12-29
KR100369697B1 (ko)	2003-02-05
MY129189A (en)	2007-03-30
IL134851A (en)	2007-06-17
PL340014A1 (en)	2001-01-15
SK4752000A3 (en)	2001-05-10
EA003396B1 (ru)	2003-04-24
DE69836752D1 (de)	2007-02-08
HN1998000157A (es)	1999-06-02

Publication	Publication Date	Title
DK1021410T3 (da)	2007-04-02	Prostaglandinagonister og deres anvendelse til behandling af knogletilstande
NO972983D0 (no)	1997-06-26	Sulfonamider og deres anvendelse
NO20001323D0 (no)	2000-03-14	Dipeptid-apoptose inhibitorer og deres anvendelse
DK1083889T3 (da)	2004-04-13	Tetrahydronaphthalenforbindelser og deres anvendelse til behandling af neurodegenerative sygdomme
DK0906292T3 (da)	2003-10-27	Triazolylmercaptider og deres anvendelse som mikrobicider
NO20023043L (no)	2002-08-14	Substituerte oksazolidinoner og deres anvendelse innenfor feltet blodkoagulasjon
NO983235D0 (no)	1998-07-14	Fikstur og protese innbefattende samme
NO964958D0 (no)	1996-11-21	Aluminium-scandiumlegeringer og deres anvendelse
DK0971735T3 (da)	2008-07-07	Fremgangsmåder og præparater til behandling af inflammatorisk tarmsygdom
NO991922L (no)	1999-04-22	Heteroarylsuccinamider og deres anvendelse som metalloproteinaseinhibitorer
DK1019358T4 (da)	2008-01-14	3,3-diarylpropylaminer, deres anvendelse og fremstilling
DK1392292T3 (da)	2006-05-29	Pyranoindazoler og deres anvendelse til behandling af glaukom
NO984761D0 (no)	1998-10-12	Aminoisokinoliner og aminotienopyridinderivater og deres anvendelse som antiinflammatoriske midler
DK0961609T3 (da)	2003-08-04	Fremgangsmåde til forbedring af sundhedstilstanden af hår og hovedbund
NO995513L (no)	2000-01-12	N-triazolyl-2-indolkarboksamider og deres anvendelse som CCK-
DK0898566T3 (da)	2003-03-03	Substituerede benzylaminer og anvendelse deraf til behandling af depression
DK0764157T3 (da)	2002-04-22	Benzopyraner og deres anvendelse som terapeutiske midler
NO986034D0 (no)	1998-12-22	Kombinasjoner omfattende VX 478, ZidovudÞn, FTC og/eller 3TC for anvendelse
DK0983271T3 (da)	2004-05-10	Carbocyklisk nucleosidhemisulfat og anvendelsen deraf i behandlingen af virusinfektioner
DK1702623T3 (da)	2009-01-19	Anvendelse af interferon-gamma til behandling af hjertehypertrofi
NO20013085D0 (no)	2001-06-21	Fosfororganiske forbindelser og deres anvendelse
NO20005502D0 (no)	2000-11-01	Polymerer og deres anvendelse
NO984921D0 (no)	1998-10-22	Tienopyridinderivater og deres anvendelse
DK0776899T3 (da)	2000-07-10	Mellemprodukter og deres anvendelse til fremstilling af N,N'-forbundne bisindolylmaleimider
GB9708067D0 (en)	1997-06-11	Rapid and long lasting biocidal system and its use to the treatment of hard surfaces